According to a filing with the U.S. Securities and Exchange Commission (SEC) on February 17, 2026, investment management firm Inherent Management Corp. increased its holdings in Sotera Health Company (SHC) by a total of 200,050 shares in the fourth quarter. Based on the average closing price for that quarter, the value of this additional purchase was approximately $3.31 million. By the end of the quarter, the reported value of this position had increased by $5.39 million, reflecting both the newly acquired shares and changes in Sotera Health’s stock price.
Following this increase, Sotera Health’s share of Inherent Management Corp.’s 13F assets reached 10.6%. As of last Friday, Sotera Health’s stock closed at $13.50. The stock has risen 13% over the past year, while the S&P 500 index gained approximately 16% over the same period, indicating underperformance relative to the broader market.
Public information shows that Sotera Health is a company providing sterilization services (including gamma irradiation, electron beam, and ethylene oxide processing), laboratory testing, and consulting solutions for the medical device, pharmaceutical, food, and specialty industries. The company’s revenue is primarily derived from three segments: sterilization, laboratory testing, and consulting services. Its clients span the globe and include medical device manufacturers, pharmaceutical companies, and stakeholders in the food, agriculture, and specialty commercial sectors. As a leading provider of sterilization and laboratory testing services, the company supports critical supply chains for the healthcare and related industries through its large-scale operations. With a broad customer base and a strong emphasis on compliance and quality assurance, its integrated service capabilities and global footprint position it as a key partner for clients operating under stringent safety and testing standards.
From an investment perspective, Sotera Health’s fundamentals continue to progress steadily. The company recently achieved its twentieth consecutive year of revenue growth, with sales increasing by approximately 6% to $1.16 billion, while adjusted EBITDA rose to nearly $600 million. Market concerns appear to be more focused on external factors: since the end of the previous quarter, the company’s stock price has declined by approximately 23%, with worries over litigation risks, leverage levels, and regulatory scrutiny overshadowing its relatively solid fundamental performance. Despite improvements in net income and a healthier balance sheet, investors have remained risk-averse. This sentiment was further reflected in a large secondary offering this month, in which existing investors—primarily private equity firms Warburg Pincus and GTCR, which typically exit after holding stakes for several years—sold 25 million shares.
Within Inherent Management Corp.’s portfolio, which is predominantly composed of broad-based ETFs and defensive assets such as NextEra Energy, the position in Sotera Health appears relatively concentrated and reflects a distinctive judgment. A position exceeding 10% of the portfolio signals the firm’s confidence in the company’s fundamentals, a decision that seems unaffected by recent stock price fluctuations.
